MedTrace Logo

Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting

NCT04013386 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-01-03

No results posted yet for this study

Summary

Laparoscopic sleeve gastrectomy (LSG) is an emerging treatment modality among the various types of surgical approach to obesity (1). The incidence of PONV in obese patients undergoing bariatric surgery, who did not receive antiemetic prophylaxis, is high at nearly 70-80 % (2,3). Postoperatively, bariatric patients appear to suffer from nausea and vomiting more frequently than normal weight or obese patients.

Conditions

  • Nausea and Vomiting, Postoperative

Interventions

DRUG

Aprepitant and Dexamethasone

Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI

DRUG

Mirtazapine and Dexamethasone

Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI

DRUG

Dexamethasone

Dexamethasone 8 mg IVI

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Tarek Mohamed Ashoor, MD · Faculty of Medicine, Ain- shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-15
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04013386 on ClinicalTrials.gov